Inogen, Inc. (NASDAQ:INGN) Holdings Raised by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Inogen, Inc. (NASDAQ:INGN) by 312.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 174,625 shares of the medical technology company’s stock after purchasing an additional 132,287 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.74% of Inogen worth $1,694,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in INGN. Divisadero Street Capital Management LP lifted its position in shares of Inogen by 682.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after buying an additional 2,046,766 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Inogen by 29.3% in the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after acquiring an additional 129,307 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Inogen in the second quarter valued at approximately $651,000. Monaco Asset Management SAM bought a new position in shares of Inogen during the second quarter valued at approximately $610,000. Finally, Stokes Family Office LLC raised its position in shares of Inogen by 162.1% during the 2nd quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company’s stock worth $927,000 after purchasing an additional 70,500 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on INGN. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Price Performance

INGN opened at $9.78 on Tuesday. The stock’s 50 day moving average price is $9.62 and its 200 day moving average price is $9.62. The stock has a market cap of $232.96 million, a P/E ratio of -4.17 and a beta of 1.04. Inogen, Inc. has a 12 month low of $4.93 and a 12 month high of $13.33.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.